The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for drug-medical device combination products at its injectable facility in Nagpur. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.

Nilesh Gupta, MD, Lupin said, “We are pleased to have received the EIR from the US FDA for drug-device combination products at our Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs."